Shionogi's diversification continues with $2bn IntraBio buy
Shionogi has agreed to acquire rare-disease specialist IntraBio for about $2 billion, extending the Japanese drugmaker's push beyond its core anti-infective business into neurology.
Shionogi
TYO: 4507 $2661.00 JPY
Discovery-based pharmaceutical company (Shionogi & Co., TYO:4507, Osaka, Japan, founded 1878) with US subsidiary marketing Fetroja (MDR Gram-negative antibiotic), Radicava ORS (ALS), and Xocova (COVID-19 antiviral).
Company Info
Upcoming Milestones & Key Dates
2026-09-10
Clinical Data
Stroke drug mid-stage failure reported
Clinical Development Pipeline
Fetroja (cefiderocol)
Target: Siderophore cephalosporinRadicava ORS (edaravone)
Target: Free radical scavengerXocova (ensitrelvir)
Target: 3CL proteaseRecent News
Leadership Team
Isao Teshirogi
Global CEO, Shionogi & Co.
Nathan McCutcheon
President & CEO, Shionogi Inc. (US)
Margaret Borys
EVP & Chief Commercial Officer (US)